ERBB2 and breast carcinoma: The majority of HER2 positive breast cancer patients are treated with anthracycline-based chemotherapy followed by anti HER2 therapy (mainly trastuzumab) to enhance response to treatment [17].Even when treatments are given sequentially, cardiotoxicity when trastuzumab is coupled with an anthracycline still warrants careful attention [18].